Prostate Cancer Claims for a Personalized Medicine.
作者信息
Lazzeri Massimo
机构信息
Department of Urology, Istituto Clinico Humanitas IRCCS, Clinical and Research Hospital, Rozzano, Milan, Italy.
出版信息
N Am J Med Sci. 2015 Oct;7(10):436-7. doi: 10.4103/1947-2714.168661.
Abstract
摘要
相似文献
1
Prostate Cancer Claims for a Personalized Medicine.
N Am J Med Sci. 2015 Oct;7(10):436-7. doi: 10.4103/1947-2714.168661.
2
Incorporating imaging into personalized medicine for the detection of prostate cancer: Pharmacological research-Urogenital pharmacology.
Pharmacol Res. 2016 Dec;114:163-165. doi: 10.1016/j.phrs.2016.10.020. Epub 2016 Oct 21.
3
Between hype and hope: What is really at stake with personalized medicine?
Med Health Care Philos. 2016 Sep;19(3):423-30. doi: 10.1007/s11019-016-9697-2.
4
Validation of an Algorithm for Claims-based Incidence of Prostate Cancer.
Epidemiology. 2019 May;30(3):466-471. doi: 10.1097/EDE.0000000000001007.
5
Noncoding RNA for personalized prostate cancer treatment: utilizing the 'dark matters' of the genome.
Per Med. 2017 Mar;14(2):159-169. doi: 10.2217/pme-2016-0090. Epub 2017 Jan 25.
6
Intended Versus Inferred Treatment After F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry.
J Nucl Med. 2018 Mar;59(3):421-426. doi: 10.2967/jnumed.117.205047. Epub 2017 Nov 30.
7
Gene‒Prostate-Specific-Antigen-Guided Personalized Screening for Prostate Cancer.
Genes (Basel). 2019 Aug 24;10(9):641. doi: 10.3390/genes10090641.
8
Oncotyrol--Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research.
Z Evid Fortbild Qual Gesundhwes. 2015;109(4-5):330-40. doi: 10.1016/j.zefq.2015.06.012. Epub 2015 Jul 28.
9
Patenting personalized medicines in the UK, Europe and USA.
Pharm Pat Anal. 2014 Mar;3(2):163-9. doi: 10.4155/ppa.14.3.
10
Personalized Decision Making for Biopsies in Prostate Cancer Active Surveillance Programs.
Med Decis Making. 2019 Jul;39(5):499-508. doi: 10.1177/0272989X19861963. Epub 2019 Jul 18.
引用本文的文献
1
Offsetting Expression Profiles of Prognostic Markers in Prostate Tumor vs. Its Microenvironment.
Front Oncol. 2019 Jun 26;9:539. doi: 10.3389/fonc.2019.00539. eCollection 2019.
2
Prostate Cancer Mortality-To-Incidence Ratios Are Associated with Cancer Care Disparities in 35 Countries.
Sci Rep. 2017 Jan 4;7:40003. doi: 10.1038/srep40003.
本文引用的文献
1
Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis.
Eur Urol. 2016 Jan;69(1):107-15. doi: 10.1016/j.eururo.2014.11.038. Epub 2014 Dec 4.
2
Prostate cancer in the elderly patient.
J Clin Oncol. 2014 Aug 20;32(24):2523-30. doi: 10.1200/JCO.2014.55.1531.
3
Focal therapy meets prostate cancer.
Lancet. 2010 Sep 25;376(9746):1036-7. doi: 10.1016/S0140-6736(10)60594-6.
Zotero 插件